Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

Marc Weiner, William Burman, Andrew Vernon, Debra Benator, Charles A. Peloquin, Awal Khan, Stephen Weis, Barbara King, Nina Shah, Thomas Hodge

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC0-12] was 36 μg·hour/ml in failure/relapse versus 56 μg·hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis monoresistant to rifamycin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration-time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.

Original languageEnglish
Pages (from-to)1341-1347
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume167
Issue number10
DOIs
StatePublished - 15 May 2003

Fingerprint

rifapentine
Isoniazid
Tuberculosis
Rifampin
Recurrence

Keywords

  • Isoniazid
  • Pharmacokinetics
  • Rifapentine
  • Treatment
  • Tuberculosis

Cite this

Weiner, Marc ; Burman, William ; Vernon, Andrew ; Benator, Debra ; Peloquin, Charles A. ; Khan, Awal ; Weis, Stephen ; King, Barbara ; Shah, Nina ; Hodge, Thomas. / Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. In: American Journal of Respiratory and Critical Care Medicine. 2003 ; Vol. 167, No. 10. pp. 1341-1347.
@article{df62d060953a48219b47946bd4a6dbea,
title = "Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine",
abstract = "To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC0-12] was 36 μg·hour/ml in failure/relapse versus 56 μg·hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis monoresistant to rifamycin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration-time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.",
keywords = "Isoniazid, Pharmacokinetics, Rifapentine, Treatment, Tuberculosis",
author = "Marc Weiner and William Burman and Andrew Vernon and Debra Benator and Peloquin, {Charles A.} and Awal Khan and Stephen Weis and Barbara King and Nina Shah and Thomas Hodge",
year = "2003",
month = "5",
day = "15",
doi = "10.1164/rccm.200208-951OC",
language = "English",
volume = "167",
pages = "1341--1347",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. / Weiner, Marc; Burman, William; Vernon, Andrew; Benator, Debra; Peloquin, Charles A.; Khan, Awal; Weis, Stephen; King, Barbara; Shah, Nina; Hodge, Thomas.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 167, No. 10, 15.05.2003, p. 1341-1347.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

AU - Weiner, Marc

AU - Burman, William

AU - Vernon, Andrew

AU - Benator, Debra

AU - Peloquin, Charles A.

AU - Khan, Awal

AU - Weis, Stephen

AU - King, Barbara

AU - Shah, Nina

AU - Hodge, Thomas

PY - 2003/5/15

Y1 - 2003/5/15

N2 - To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC0-12] was 36 μg·hour/ml in failure/relapse versus 56 μg·hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis monoresistant to rifamycin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration-time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.

AB - To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC0-12] was 36 μg·hour/ml in failure/relapse versus 56 μg·hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis monoresistant to rifamycin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration-time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.

KW - Isoniazid

KW - Pharmacokinetics

KW - Rifapentine

KW - Treatment

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0037614780&partnerID=8YFLogxK

U2 - 10.1164/rccm.200208-951OC

DO - 10.1164/rccm.200208-951OC

M3 - Article

C2 - 12531776

AN - SCOPUS:0037614780

VL - 167

SP - 1341

EP - 1347

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -